BefejeződöttFázis nélkül
Real-world Outcomes of Aplastic Anemia Patients Treated With Eltrombopag: A Medical Claims Database Study
A legfontosabb adatok
- Ki végzi
- Novartis Pharmaceuticals
- Hol
- East Hanover (Egyesült Államok)A helyszín megnézése
- Azonosító
- Állapot
- Befejeződött
- Résztvevők
- 2517 fő vett részt
- Kezdés
- 2021. júl. 14.
- Befejezés
- 2024. máj. 17.
- A vizsgálat típusa
- Megfigyeléses, 2 csoport
- A regiszteradat frissítve
- 2025. május 28.
Ki vehet részt
- Életkor
- 15 év – 90 év
- Nem
- Nők és férfiak
- Egészséges önkéntesek
- Nem vehetnek részt
A regiszter feltételei, szó szerint
Mind a 12 feltétel megnézéseKevesebb
Ki vehet részt
- Patients with:; At least one confirmed diagnosis of AA registered during the baseline period, or; At least one confirmed diagnosis of idiopathic thrombocytopenic purpura (International Classification of Diseases, 10th Revision [ICD10] code: D69.3) registered before the index date and at least one confirmed diagnosis of AA during the follow-up period
- Had at least 6 months of continuous enrolment prior to the index date; Confirmed diagnosis was defined as having ≥1 inpatient or ≥2 outpatient claims with a relevant ICD-10 code and without any doubtful flag; Continuous enrolment (being continuously followed in the database) was defined as having at least one claim every semester
- Had at least one confirmed diagnosis of AA registered before the index date,
- Had at least one procedure for any type of transfusion such as red blood cell transfusion, platelet transfusion, or granulocyte transfusion registered during the baseline period or within 4 weeks after the index date,
- Had at least 6 months of continuous enrolment prior to the index date,
- Had at least a 6-month follow-up period
Ki nem vehet részt
- Not receiving ATG, CSA, ETB or romiplostim (ROM) during the selection period,
- Not receiving ATG, CSA, ETB or ROM during the selection period,
- Had a diagnosis of acute myeloid leukemia (AML), chronic myelomonocytic leukemia (CMML), myelofibrosis, other hematological malignancies, or cataract before the index date; Inclusion and exclusion criteria for the effectiveness population:
- Had a diagnosis of AML, CMML or other hematological malignancies before the index date
- Had at least one prescription of ATG, CSA, ETB or ROM before the index date,
Egyéb feltételek
- Inclusion and exclusion criteria for the safety population:
Helyszínek itt: Egyesült Államok
- NovartisEast Hanover, Egyesült Államok
A vizsgálatról
Mit akar kideríteni a vizsgálat
The main goal of this study was to investigate the effectiveness and safety of eltrombopag (ETB) when compared to other treatments in Japanese aplastic anemia (AA) patients using data from the Medical Data Vision (MDV) hospital-based database.
A vizsgálat 2 csoportja
- Anatomical Therapeutic Chemical (ATG)-free Cohort
Japanese patients with AA from the MDV database who received treatment with ciclosporin A (CSA) alone, ETB alone, or a combination of CSA and ETB.
- ATG-Inclusive Cohort
Japanese patients with AA from the MDV database who received one of the following treatment combinations: CSA and ATG or CSA and ETB and ATG.
Adatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- Real-world Outcomes of Aplastic Anemia Patients Treated With Eltrombopag: A Retrospective Medical Claims Database Study (Eltrombopag for Aplastic Anemia)
- A regiszteradat frissítve
- 2025. május 28.